Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
102.65
(
-1.71%
)
Bitcoin
70,452.33
(
0.79%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 76383

Wednesday, 04/22/2009 7:05:38 AM

Wednesday, April 22, 2009 7:05:38 AM

Post# of 257262

RDEA: Valeant has an option to license this compound [RDEA-806] post phase 2B and pre phase 3.

For the HIV program (as opposed to the gout program), this option may be moot insofar as RDEA does not plan to start a phase-2b trial without a partner.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now